dr. shuch on caveats of avelumab/axitinib combination in rcc
Published 5 years ago • 195 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:47
dr. choueiri discusses avelumab/axitinib data in rcc
-
2:15
dr. shuch on the impact of the surtime trial in advanced rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:59
dr. shuch on considerations for appropriate treatment in advanced rcc
-
1:38
dr. choueiri on avelumab plus axitinib in mrcc
-
10:15
novel combinations in mrcc: axi/pembro vs axi/avelumab
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
1:06
dr. mcgregor on the utility of axitinib/avelumab in advanced rcc
-
1:50
dr. shuch on role of cytoreductive nephrectomy in rcc
-
3:18
exploring the combination of first-line avelumab/axitinib in hcc
-
0:57
avelumab and axitinib for the treatment of advanced rcc
-
1:05
dr. shuch on biology of non-clear cell rcc
-
1:24
final results of avelumab and axitinib in rcc in the javelin renal 101 trial
-
2:32
avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients
-
4:20
neoadjuvant avelumab plus axitinib active in high-risk rcc | axel bex
-
1:37
immunotherapy combinations improve survival in advanced renal cell carcinoma
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
4:30
neoadjuvant axitinib and avelumab for high-risk renal cell carcinoma
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma